HPV False Positive: What It Means and How to Address It

Most positive HPV test results are not false positives in the strict laboratory sense; the test genuinely detected HPV DNA or RNA in the sample. The more accurate term for what most people mean when they search “HPV false positive” is a clinically misleading positive: the virus is present, but it will never cause cancer. Because most HPV infections clear on their own without doing harm, the gap between “virus detected” and “disease ahead” is enormous, and that gap is where confusion, anxiety, and unnecessary procedures tend to pile up.

Why a Positive HPV Test Often Means Less Than It Sounds

HPV is extraordinarily common. Among young women shortly after they become sexually active, infection rates approach 40 to 50 percent, and the vast majority of those infections are cleared by the immune system within one to two years without ever producing precancerous changes.¹ A positive HPV test simply tells you the virus is there right now. It says nothing about whether it has been there for months, whether it is actively causing cell changes, or whether your immune system is already in the process of eliminating it. For most people, the answer to all three of those questions is reassuring.

The trouble is that HPV DNA tests are designed to be extremely sensitive. They cast a wide net on purpose, because missing a true precancer is far more dangerous than flagging an infection that turns out to be harmless. But that deliberate sensitivity means the test picks up a large number of infections that will resolve without treatment. One modeling study estimated that for a cohort of one million women screened with both Pap and HPV testing, the number of colposcopies would rise to about 4.7 million over a lifetime, with roughly 3.2 million of those colposcopies triggered by results that ultimately turn out to be falsely positive in clinical terms.² Those numbers capture the scale of the problem: HPV testing saves lives, but it also generates a lot of alarm that leads nowhere.

True Technical False Positives Do Happen

There is a smaller but real category of genuinely erroneous results, where the test signals HPV even though the virus is not actually present. This happens mainly through cross-reactivity, when a test designed to detect high-risk HPV strains accidentally reacts to low-risk strains that pose no cancer threat. A study comparing three widely used HPV assays found that cross-reactivity to low-risk genotypes occurred in about 2.2 percent of samples on the Hybrid Capture 2 (HC2) platform, about 1.2 percent on the cobas test, and about 0.7 percent on the APTIMA assay.³ Only a handful of samples cross-reacted on all three tests, which tells you that the problem is assay-specific rather than something inherent in the sample.

Sample contamination in the lab is another source of true false positives, though modern quality assurance practices have made this rare. The bottom line is that genuine technical errors account for a small fraction of “false” positives. The much bigger contributor is the biological reality that a detected infection is usually harmless.

DNA Tests Versus mRNA Tests

Not all HPV tests are created equal, and the type of test used has a direct impact on how many clinically misleading positives you can expect. Most screening programs use HPV DNA tests, which look for the genetic material of the virus itself. These are highly sensitive but not great at distinguishing a transient infection from one that is actively driving precancerous changes.

Newer tests that look for HPV E6/E7 mRNA take a different approach. Instead of just detecting the virus’s DNA, they detect messenger RNA produced when the virus is actively expressing the genes most responsible for turning cells cancerous. A study comparing the two approaches found that E6/E7 mRNA quantification had a specificity of 96 percent based on normal cytology, compared to just 82 percent for the HC2 DNA test. When measured against the absence of precancerous lesions on biopsy, the mRNA test’s specificity was 85 percent versus 35 percent for HC2.⁴ That 35 percent specificity for HC2 means that roughly two out of three women without precancer still tested positive on the DNA test, a staggering rate of clinically misleading results.

A systematic review and meta-analysis confirmed the broader pattern. Across multiple studies, HPV mRNA testing showed comparable sensitivity to DNA testing for detecting significant cervical abnormalities, while specificity was significantly higher across all mRNA platforms evaluated.⁵ In plain language, mRNA tests catch nearly the same number of real problems but flag far fewer harmless infections. If your positive HPV result came from an mRNA-based test, it carries more clinical weight than a result from a DNA-only test.

What Happens After a Positive Result

The days of “positive test equals immediate colposcopy” are largely over, at least in guidelines. The 2019 ASCCP (American Society for Colposcopy and Cervical Pathology) consensus guidelines shifted away from rigid algorithms tied to specific test results and moved toward a risk-based framework. Instead of telling clinicians exactly what to do for every combination of Pap and HPV results, the guidelines estimate a patient’s probability of having or developing high-grade precancer based on their current results, their screening history, and whether they have been treated for precancer before. Different levels of estimated risk trigger different actions: routine re-screening, closer surveillance at one or three years, colposcopy, or treatment.⁶

For the most common scenario that worries people, a positive HPV test with a normal Pap smear (sometimes called a discordant result), the recommended path is typically a repeat co-test in one year rather than immediate colposcopy. An alternative approach is to check specifically for HPV types 16 and 18; if either is found, colposcopy is warranted sooner, while other high-risk types can be monitored with follow-up testing.⁷ The rationale is straightforward: most women in this discordant group have a low near-term risk of cancer, and sending all of them straight to colposcopy would mean a huge number of unnecessary invasive procedures. But the five-year risk is still meaningfully higher than for women who test negative on everything, so they cannot simply be ignored.

Why HPV 16 and 18 Get Special Attention

Among the roughly fourteen HPV types classified as high-risk, types 16 and 18 are responsible for the majority of cervical cancers. Genotyping, the process of identifying which specific HPV type is present, has become a key triage tool precisely because it helps separate higher-risk positives from lower-risk ones.

Data from the ASCCP’s own risk analysis showed that women with a normal Pap smear who tested positive for HPV 16 had an immediate risk of high-grade precancer of about 5.3 percent, high enough to justify colposcopy. Women positive for HPV 18 with normal cytology also warranted colposcopy based on their known elevated risk of cervical cancer, even though their short-term numbers were lower.⁸ A separate study in a screening population found that women who were HPV 16/18 positive with normal cytology had an 11 percent absolute risk of high-grade precancer, reinforcing the case for immediate follow-up in this subgroup.⁹

For women positive for other high-risk HPV types but negative for 16 and 18, the picture is much more reassuring. Their risk profile is low enough that a repeat test in a year is generally considered safe. Genotyping, in other words, is the tool that prevents the broadest category of clinically misleading positives from being treated as emergencies. If your provider ordered genotyping and your result came back positive for a non-16/18 type with normal cytology, you are in the lowest-risk positive group.

Newer Triage Tools and Where the Field Is Heading

Even genotyping leaves some uncertainty, especially for women positive for non-16/18 high-risk types. Researchers have been testing additional triage methods to better identify who among HPV-positive women actually needs a colposcopy. One promising approach uses dual-stain testing for the biomarkers p16 and Ki-67, which indicate that the virus is actively disrupting cell growth controls.

An Italian screening study compared several triage strategies head-to-head. For detecting high-grade precancer among HPV-positive women, p16/Ki-67 dual staining had a sensitivity of 85 percent, compared to 67.9 percent for cytology alone and 56 percent for HPV 16/18 typing alone. When dual staining was combined with genotyping, sensitivity climbed to 91.1 percent. Women who tested negative on p16/Ki-67 triage had a one-year risk of high-grade precancer of only about 1 percent, low enough that researchers suggested the surveillance interval could be extended to two or three years.¹⁰ That kind of extension matters for patients: it means fewer visits, fewer anxious waits for results, and fewer unnecessary procedures.

How Vaccination Changes the Math

HPV vaccination adds another layer to the false-positive question. As vaccinated cohorts age into screening, the prevalence of HPV 16 and 18 drops, which means a higher proportion of positive HPV tests will be detecting other types that are less likely to cause cancer. The predictive value of a positive screening result shifts.

A study across three U.S. healthcare systems found that the positive predictive value of a screening result prompting colposcopy referral was consistently lower in vaccinated women than in unvaccinated women across all age groups. Among 25- to 29-year-olds, the difference was statistically significant: about 16.4 percent of colposcopy referrals in vaccinated women found precancer, compared to about 19.8 percent in unvaccinated women.¹¹ In practical terms, a vaccinated person who gets a positive HPV test is even more likely than an unvaccinated person to be dealing with a clinically insignificant finding. Screening guidelines have not yet been formally adjusted for vaccination status, but this is a gap that researchers are actively working to close.

The Emotional Weight of a Positive Result

Numbers and risk estimates are cold comfort when you are the one staring at a positive result. Research consistently shows that testing positive for HPV creates real psychological distress, and the distress often has little to do with the actual medical risk. A qualitative study of women in cervical screening found that a positive HPV result was associated with feelings of stigma, anxiety, and stress. Women worried about their sexual relationships and were reluctant to disclose the result to partners or friends, in large part because HPV is sexually transmitted and linked in the public mind to cancer.¹² A systematic review echoed these findings, noting that psychosexual concerns spanned women’s current and past relationships.¹³

Much of this distress is fueled by framing HPV as a sexually transmitted infection in the traditional sense. Experts involved in developing communication tools for clinicians have recommended explicitly avoiding an STI framework when discussing HPV screening results. Their guidance emphasizes acknowledging the patient’s fear (especially fear of cancer), empowering patients to understand next steps, and focusing on the clinical follow-up plan rather than the route of transmission.¹⁴ If your provider delivered your positive result with little context and you left the office feeling panicked, you are far from alone, and seeking a follow-up conversation to understand the specifics is entirely reasonable.

Guideline Adherence Is Uneven

One underappreciated source of unnecessary worry is that providers do not always follow the guidelines. A study at a community health network found that about two-thirds of cervical screening encounters were nonadherent with ASCCP recommendations. The most common problems were screening at inappropriately short intervals (performing a test too soon), failing to include HPV co-testing when indicated, and mismanaging results by either skipping a needed colposcopy or ordering one that was not warranted.¹⁵ That last category is worth noting: about a third of the mismanagement cases involved unnecessary colposcopy, meaning the patient was subjected to an invasive procedure they did not need based on their risk profile.

If you have received a positive HPV result and your provider is recommending immediate colposcopy despite a normal Pap smear and no genotyping for HPV 16/18, it is worth asking whether your case meets the risk threshold for that step. The ASCCP’s risk tables are publicly available online, and a second opinion from a gynecologist who specializes in cervical screening is a reasonable step if you feel uncertain.

HPV Testing During Pregnancy

Pregnancy introduces its own questions about HPV test results. Some research has suggested that pregnancy may increase HPV detection rates, possibly because hormonal changes promote viral replication or because the immune shifts of pregnancy reduce clearance. One study found that 28 percent of pregnant women with a normal Pap smear had a positive HPV DNA test, compared to about 12 percent of non-pregnant women, and that positive results were more common in the second half of pregnancy. Other research has found no statistically significant difference in detection rates between pregnant and non-pregnant women.¹⁶ The conflicting findings mean that a positive HPV test during pregnancy may partly reflect the physiology of pregnancy itself rather than a new or worsening infection. Standard practice is to defer colposcopy during pregnancy unless there is a strong suspicion of invasive cancer, and to re-evaluate after delivery.

Self-Collection and Test Accuracy

Self-collection kits for HPV testing are becoming more common as a strategy to reach people who face barriers to clinic-based screening. Whether self-collection affects the likelihood of a misleading result depends on which study you read. A large randomized trial (the IMPROVE study) found that HPV testing on self-collected samples had sensitivity and specificity that did not significantly differ from clinician-collected samples for detecting precancerous changes.¹⁷ However, a more recent meta-analysis pooling data from multiple studies concluded that self-collected samples have significantly lower sensitivity for detecting high-risk HPV and high-grade cervical lesions, even though specificity was comparable.¹⁸

The tension between these findings likely reflects differences in the specific self-collection devices, instructions, and testing platforms used across studies. For the false-positive question, self-collection does not appear to increase the rate of incorrect positive results (specificity is similar either way). The bigger concern with self-collection is false negatives, missing a real infection, which is the opposite problem but still worth being aware of if you are relying on a home kit.

What You Can Actually Do With a Positive Result

If you have tested positive for HPV and are trying to figure out what to do next, a few practical steps can help you navigate the situation without either panicking or ignoring it entirely.

Ask which test was used. An mRNA-based test (like APTIMA) carries more clinical weight than a DNA-only test (like HC2). If you tested positive on a DNA test alone, the chance that the result is clinically meaningless is higher.
Ask about genotyping. If your result was positive for HPV but your provider has not specified whether types 16 or 18 were detected, request that information. It changes the recommended follow-up path significantly.
Check your Pap result. A positive HPV test with a normal Pap smear is a very different situation from a positive HPV test with abnormal cells. The combination matters more than either result alone.
Understand the timeline. For most discordant results (HPV positive, Pap normal, not type 16 or 18), the standard recommendation is a repeat test in one year, not immediate intervention. If your provider is suggesting something different, ask why your risk level warrants it.
Know that clearance is the norm. The majority of HPV infections, even high-risk types, are cleared by the immune system. A positive result today does not mean a positive result next year.

The anxiety surrounding HPV screening results is arguably the most underappreciated cost of the current screening paradigm. The tests work; they have contributed to dramatic reductions in cervical cancer rates. But the same sensitivity that makes them effective also guarantees a flood of positive results in people who will never develop disease. Understanding that gap between “detected” and “dangerous” is the single most useful thing you can take away from a positive HPV test.